drugset
Drugs / [18F]FET-βAG-TOCA
last change Feb 2024 re-read 3 minutes ago

[18F]FET-βAG-TOCA

also known as [18F]fluoroethyl-triazole-[Tyr3]-octreotate
Investigated by
Imperial College Healthcare NHS Trust · Imperial College London · Invicro · Newcastle University · Royal Marsden NHS Foundation Trust · The Christie NHS Foundation Trust
+1 more · University of Manchester

Trials 1

today NCT06456723 · Ph 1/2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06456723 May 2014 → Oct 2018 neuroendocrine neoplasm Imperial College London Completed Met primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as [18F]FET-βAG-TOCA “We have shown that [18F]fluoroethyl-triazole-[Tyr3]-octreotate ([18F]FET-βAG-TOCA) has favorable dosimetry and biodistribution.” PMID 38331457 ↗ Feb 2024
1

NCT06456723 ↗
Known as [18F]fluoroethyl-triazole-[Tyr3]-octreotate “We have shown that [18F]fluoroethyl-triazole-[Tyr3]-octreotate ([18F]FET-βAG-TOCA) has favorable dosimetry and biodistribution.” PMID 38331457 ↗ Feb 2024
Route Intravenous “Single I.V. administration of a \[18F\]fluoroethyl triazole \[Tyr3\]Octreotate (\[18F\]-FET-βAG-TOCA).” NCT06456723 ↗